Resources
Did you mean
GlaxoSmithKline Plc. (17 results)
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- glaxo Profit Fall as Generics Weigh
- By Ben Hirschler LONDON (Reuters) - GlaxoSmithKline Plc GSK profits fell 5 percent in the first quarter, hit by tumbling sales of diabetes drug Avandia and generic competition to other products, the world's second biggest drugmaker said. The decline was less than analysts...
- News items 2008-04-23
- glaxo Profits Fall as Avandia and Generics Weigh
- By Ben Hirschler LONDON (Reuters UK) - GlaxoSmithKline GSK profits fell 5 percent in the first quarter, hit by tumbling sales of diabetes drug Avandia and generic competition to other products, the world's second biggest drugmaker said. The decline was less than analysts had feared, helped...
- News items 2008-04-23
- glaxo Wins FDA Approval For Wider Advair Use
- WASHINGTON (Reuters) - U.S. health regulators have said GlaxoSmithKline Plc's GSKGSK Advair is safe and effective to more widely treat patients with chronic obstructive pulmonary disease COPD, the drugmaker said on Wednesday. Glaxo's approval comes the same day as rival AstraZeneca...
- News items 2008-04-30
- glaxo Wins U.S. FDA Approval For Wider Advair Use
- By Susan Heavey WASHINGTON (Reuters UK) - U.S. health regulators have said GlaxoSmithKline Plc's GSKGSK Advair is safe and effective to more widely treat patients with chronic obstructive pulmonary disease COPD, the drugmaker said on Wednesday. Glaxo's approval comes the same day as rival AstraZeneca...
- News items 2008-04-30
- glaxo Makes Like Ponce de Leon With Sirtris Buy
- You can't fault GlaxoSmithKline for temerity. The U.K. drugmaker's unexpectedly large $720 million bid for Sirtris Pharmaceuticals represents a gutsy bet that the Massachusetts biotech really has a handle on a class of drugs that slow aging. Not that anyone at either company is eager to describe their work that...
- Blog posts 2008-04-22
- glaxo to Buy Biotech Sirtris in $720 Mln Deal
- By Ransdell Pierson NEW YORK (Reuters UK) - GlaxoSmithKline GSK said on Tuesday it had agreed to buy biotechnology company Sirtris Pharmaceuticals Inc SIRT for $720 million (360.69 million pounds) in cash, in hopes its medicines that modulate an aging-related family of enzymes will be...
- News items 2008-04-22
- glaxo-Regulus Kicks Off an miRNA Land Grab
- GlaxoSmithKline's willingness to bet up to $600 million on a tiny biotech called Regulus Therapeutics kicks off the latest pharma land grab -- this one for treatments that rely on tiny molecules called microRNAs, or miRNAs for short. New drug technologies -- or "modalities," as the industry...
- Blog posts 2008-04-18
- glaxo Gets an FDA Warning... With Teeth
- Well before Vytorin became a cause célèbre -- which is to say, about a year ago -- GlaxoSmithKline's Avandia was the drug getting slapped around by critics for, in that case, possible heart problems that had possibly been downplayed or ignored. That case, which led to new warnings on the...
- Blog posts 2008-04-12
Additional Resources
- Business allies rally to Brown in row over tax exodus
- Jean-Pierre Garnier, the chief executive of the world's fourth biggest pharmaceutical group, GlaxoSmithKline, offered respite to the beleaguered Government yesterday, saying that his company does not intend to join the exodus of those leaving the UK for lighter taxes in Ireland. Mr Garnier, an ally of Gordon...
- Articles 2008-05-08
- Medicago Appoints New VP Manufacturing
- Medicago Inc. (TSX VENTURE: MDG) today announced that Brigitte Barbeau has been appointed Vice President, Manufacturing, and is expected to join the company on May 26, 2008. In this newly created position, Ms. Barbeau will lead the Company's manufacturing functions to accelerate the development of Medicago's H5N1 pandemic influenza vaccine...
- Articles 2008-05-07
- Targacept Reports First Quarter 2008 Financial Results
- WINSTON-SALEM, N.C. -- Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics[TM], today reported its financial results for the first quarter ended March 31, 2008. Targacept reported a net loss of $5.8 million for the first quarter of 2008,...
- Articles 2008-05-06
- Oncolin Therapeutics Announces That Dr. Randall K. Johnson Has Agreed to Join Its Scientific Advisory Board
- HOUSTON -- Oncolin Therapeutics, Inc., (OTCBB:OCOL) is pleased to announce that Dr Randall K. Johnson has agreed to join the Scientific Advisory Board of the company joining a growing number of illustrious oncologists and cancer drug developers. Dr Johnson began his career as section Head of the Experimental Chemotherapy at...
- Articles 2008-05-05
- Targacept Announces Designation of Lead Compound in Smoking Cessation Program
- Triggers Milestone Payment from GlaxoSmithKline WINSTON-SALEM, N.C. -- Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics TM, today announced the designation of a lead compound in its smoking cessation program, triggering a $500,000 milestone payment under its alliance agreement...
- Articles 2008-05-05
- Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments
- - LymphoStat-BR Phase 3 trial BLISS-52 completes enrollment ahead of previous fall 2008 projection - - AlbuferonR Phase 3 trial in genotypes 2 and 3 hepatitis C completes treatment phase - - Rights to TRAIL receptor antibodies reacquired - - GlaxoSmithKline announces plan to...
- Articles 2008-05-05
- EPIX Pharmaceuticals Initiates Phase 2b Program in Alzheimer's Disease
- Company Earns $7.5 Million Milestone From GlaxoSmithKline LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that it has begun its Phase 2b program...
- Articles 2008-05-05
- St. Cecilia clinic in New Orleans awarded $133,500 for diabetes
- Excelth Inc., Daughters of Charity Services of New Orleans and United Health Foundation said today that the Daughters of Charity Health Center at St. Cecilia has received a $133,500 commitment from GlaxoSmithKline to support the expansion of community outreach efforts to help prevent and manage diabetes. ...
- Articles 2008-05-02
- glaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
- LONDON, May 2 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc GSK announced today that Fountain Acquisition Corporation, a wholly-owned subsidiary of GSK, is commencing a cash tender offer to purchase all outstanding shares of common stock of Sirtris Pharmaceuticals, Inc. Sirtris, for $22.50 in cash without interest and less any required...
- Articles 2008-05-02
- United Health Foundation Centers of Excellence Daughters of Charity Health Center - St. Cecilia Receives New Grant Funding from glaxoSmithKline
- * GlaxoSmithKline donation significantly expands diabetes treatment in Bywater community; * Study reveals that Daughters of Charity Health Center exceeds national benchmarks for quality care NEW ORLEANS -- EXCELth, Inc., Daughters of Charity Services of New Orleans and United Health Foundation announced today that the Daughters...
- Articles 2008-05-02
- XenoPort Appoints Vincent J. Angotti as Chief Commercialization Officer
- SANTA CLARA, Calif. -- XenoPort, Inc. (Nasdaq:XNPT) announced today that Vincent J. Angotti has joined the company as senior vice president and chief commercialization officer. His near-term responsibilities will include strategic marketing, product planning and management of the commercial aspects of alliances with Astellas Pharma, Inc. and GlaxoSmithKline, or GSK,...
- Articles 2008-05-01
- POZEN To Present at Baird's 2008 Growth Stock Conference
- CHAPEL HILL, N.C. -- POZEN Inc. (NASDAQ: POZN) announced today that John R. Plachetka Pharm.D., the company's chairman, president and chief executive officer, will present at Baird's 2008 Growth Stock Conference on Tuesday, May 13, 2008 at 10:40 a.m. CT at the Four Seasons Hotel in Chicago. POZEN...
- Articles 2008-05-01
- << Previous
- page 1 of 1
- Next >>
Content Types
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
